Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
-
261
mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes.
Published 2020“…(<b>B</b>) <i>FIP200</i> and <i>ATG101</i> mRNA expressions were decreased in the primary cultured podocytes from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup>. …”
-
262
-
263
-
264
-
265
-
266
-
267
Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A
Published 2012“…The numbers of all three types of cells were significantly decreased by the 8<sup>th</sup> week of naris occlusion (<b>C</b>, red bars, <i>n</i> = 4) compared with the control group (<b>C</b>, blue bars, <i>n</i> = 5). …”
-
268
-
269
-
270
-
271
-
272
-
273
-
274
-
275
-
276
-
277
-
278
-
279
Cellular input resistance is decreased during UP states.
Published 2008“…Mean decrease was 50.9%; standard deviation was 36.6%, shown in gray bar at left. 2 of 4 interneurons showed significant decreases in resistance during the UP state and one cell actually showed an increase. …”
-
280
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”